Zhen Li, P.F. Maccarini, O.A. Arabe, V. Stakhursky, W.T. Joines and P.R. Stauffer, Duke University; M. Vogel and D. Crawford, Ansoft Corp.

Recent developments have reinvigorated clinical investigations of hyperthermia (HT) as a viable adjuvant treatment in the fight against cancer. Researchers are placing a greater emphasis on multi-modal approaches that include mild temperatures (40° to 43°C) and standard therapies like radiation and chemotherapy, than on achieving higher temperature treatments (43°...